Understand the source comparison
SS-LUP-332 Contraindications: Research Category Comparison
Hepatic Impairment (ALT/AST >2× ULN) Reduced CYP-mediated clearance increases plasma concentration 60–75%, elevates lactic acidosis risk Absolute contraindication Baseline LFTs; if borderline, repeat weekly × 4 weeks Exclude from protocols. Risk exceeds any re
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hepatic Impairment (ALT/AST >2× ULN)
- Reduced CYP-mediated clearance increases plasma concentration 60–75%, elevates lactic acidosis risk
- Absolute contraindication
- Baseline LFTs; if borderline, repeat weekly × 4 weeks
- Exclude from protocols. Risk exceeds any research value
- Severe Renal Dysfunction (eGFR <30)
- Impaired glomerular filtration creates 3.2× higher AUC, prolonged hypoglycemia exposure
- Baseline CMP with eGFR calculation; continuous glucose monitoring if eGFR 30–45
- Exclude entirely; moderate impairment (eGFR 45–60) requires dose reduction
- Type 1 Diabetes or Insulin-Dependent Type 2
- AMPK activation without endogenous counter-regulation produces uncontrolled lipolysis and ketoacidosis
- Baseline HbA1c, fasting glucose, medication history
- Never administer. Mechanism incompatible with safe glucose control
- Concurrent AMPK Modulators (Metformin, Berberine)
- Additive AMPK activation increases lactate production 2.4-fold, precipitates lactic acidosis
- Relative contraindication requiring washout
- 14-day metformin washout; 7-day berberine/resveratrol washout; baseline lactate measurement
- Safe after washout; concurrent use creates unacceptable metabolic stress
- Beta-Blocker Therapy
- Masks hypoglycemia warning symptoms (tachycardia, tremor), allows dangerous glucose nadirs without awareness
- Relative contraindication requiring enhanced monitoring
- Continuous glucose monitoring first 72 hours; protocol-mandated glucose checks every 4 hours
- Proceed only if continuous monitoring feasible; patient safety depends on early detection
- Pregnancy or Lactation (Mammalian Models)
- Unknown teratogenic potential; AMPK modulation during organogenesis may disrupt fetal development
- Pregnancy testing before enrollment in reproductive-age female subjects; reproductive toxicology data incomplete
- Exclude until reproductive safety data from animal studies meet FDA guidance thresholds
- This comparison table synthesizes documented adverse event patterns from early-phase SS-LUP-332 research. Severity classifications reflect current consensus among institutional biosafety committees reviewing metabolic intervention protocols. Researchers should note that 'relative contraindication' doesn't mean optional consideration. It means the contraindication can be managed through protocol modifications rather than automatic exclusion.